BR0115291A - Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip - Google Patents

Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip

Info

Publication number
BR0115291A
BR0115291A BR0115291-2A BR0115291A BR0115291A BR 0115291 A BR0115291 A BR 0115291A BR 0115291 A BR0115291 A BR 0115291A BR 0115291 A BR0115291 A BR 0115291A
Authority
BR
Brazil
Prior art keywords
compounds
antagonists
phenylaminoimidazoline
ketone derivatives
substituted
Prior art date
Application number
BR0115291-2A
Other languages
English (en)
Inventor
Alam Jahangir
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0115291A publication Critical patent/BR0115291A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"DERIVADOS DE 2-FENILAMINOIMIDAZOLINA FENIL CETONA SUBSTITUìDOS COMO ANTAGONISTAS DE IP". Esta invenção refere-se a compostos que são geralmente moduladores de receptores de prostaglandinas I2, particularmente antagonistas de receptores de IP, e que são representados pela fórmula geral (I) em que A, R^ 1^ e R^ 2^ são definidos no relatório descritivo; e isómeros individuais, misturas racêmicas ou não-racêmicas de isómeros, e sais ou solvatos farmaceuticamente aceitáveis dos compostos. A invenção adicionalmente refere-se a composições farmacêuticas que contêm esses compostos, a um processo para a preparação desses compostos e ao seu uso para tratar doenças associadas a dor, inflamação, estados de doença do trato urinário, estados de doença respiratória, formação de edema, ou doenças vasculares hipotensas.
BR0115291-2A 2000-11-14 2001-11-05 Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip BR0115291A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24888800P 2000-11-14 2000-11-14
PCT/EP2001/012776 WO2002040453A1 (en) 2000-11-14 2001-11-05 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists

Publications (1)

Publication Number Publication Date
BR0115291A true BR0115291A (pt) 2003-08-19

Family

ID=22941114

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115291-2A BR0115291A (pt) 2000-11-14 2001-11-05 Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip

Country Status (29)

Country Link
EP (1) EP1339694B1 (pt)
JP (1) JP4108474B2 (pt)
KR (1) KR100562605B1 (pt)
CN (1) CN1267423C (pt)
AR (1) AR035502A1 (pt)
AT (1) ATE305002T1 (pt)
AU (1) AU2180802A (pt)
BG (1) BG107814A (pt)
BR (1) BR0115291A (pt)
CA (1) CA2427900A1 (pt)
CZ (1) CZ20031596A3 (pt)
DE (1) DE60113563T2 (pt)
EC (1) ECSP034602A (pt)
ES (1) ES2248413T3 (pt)
HU (1) HUP0303156A3 (pt)
IL (1) IL155436A0 (pt)
MA (1) MA26958A1 (pt)
MX (1) MXPA03004073A (pt)
NO (1) NO20032142D0 (pt)
NZ (1) NZ525330A (pt)
PA (1) PA8532201A1 (pt)
PE (1) PE20020602A1 (pt)
PL (1) PL362549A1 (pt)
RU (1) RU2284995C2 (pt)
SK (1) SK7222003A3 (pt)
UY (1) UY27023A1 (pt)
WO (1) WO2002040453A1 (pt)
YU (1) YU37203A (pt)
ZA (1) ZA200303413B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517576A (ja) * 2003-02-14 2006-07-27 メディカル リサーチ カウンシル 病理的子宮症状の治療のためのｉｐレセプターアンタゴニスト
MXPA05011476A (es) * 2003-05-01 2005-12-12 Hoffmann La Roche Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
WO2005000247A2 (en) * 2003-06-25 2005-01-06 Smithkline Beecham Corporation 4-carboxamido quinoline derivatives for use as nk-2 and nk-3
MXPA06000269A (es) * 2003-07-09 2006-04-07 Hoffmann La Roche Tiofenilaminoimidazolinas.
JP2009524619A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のための２−イミダゾールの使用
CA2666762C (en) 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
JP5064511B2 (ja) 2006-11-02 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー 痕跡アミン関連受容体調節剤としての置換２−イミダゾール
RU2456281C2 (ru) 2006-11-16 2012-07-20 Ф. Хоффманн-Ля Рош Аг Замещенные 4-имидазолы, способ их получения и их применение
AU2007332641A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
RU2473545C2 (ru) 2007-02-02 2013-01-27 Ф.Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
BRPI0812840A2 (pt) 2007-07-02 2014-12-09 Hoffmann La Roche 2-imidazolinas
JP2010531836A (ja) 2007-07-03 2010-09-30 エフ．ホフマン−ラ ロシュ アーゲー ４−イミダゾリン及びそれらの抗うつ剤としての使用
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
WO2009019149A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2011080132A2 (en) 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889868A (en) * 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
YU37203A (sh) 2006-05-25
KR20030065512A (ko) 2003-08-06
EP1339694A1 (en) 2003-09-03
BG107814A (bg) 2004-02-27
CZ20031596A3 (cs) 2004-01-14
CA2427900A1 (en) 2002-05-23
CN1267423C (zh) 2006-08-02
NO20032142L (no) 2003-05-13
DE60113563T2 (de) 2006-07-13
HUP0303156A3 (en) 2004-03-29
ATE305002T1 (de) 2005-10-15
NO20032142D0 (no) 2003-05-13
EP1339694B1 (en) 2005-09-21
ES2248413T3 (es) 2006-03-16
JP4108474B2 (ja) 2008-06-25
PE20020602A1 (es) 2002-07-08
WO2002040453A1 (en) 2002-05-23
NZ525330A (en) 2004-10-29
MA26958A1 (fr) 2004-12-20
MXPA03004073A (es) 2003-09-04
AR035502A1 (es) 2004-06-02
ZA200303413B (en) 2004-08-02
HUP0303156A2 (hu) 2004-01-28
AU2180802A (en) 2002-05-27
IL155436A0 (en) 2003-11-23
JP2004513940A (ja) 2004-05-13
RU2284995C2 (ru) 2006-10-10
PL362549A1 (en) 2004-11-02
DE60113563D1 (de) 2006-02-02
UY27023A1 (es) 2002-06-20
ECSP034602A (es) 2003-06-25
KR100562605B1 (ko) 2006-03-17
SK7222003A3 (en) 2004-05-04
PA8532201A1 (es) 2002-08-26
CN1474813A (zh) 2004-02-11

Similar Documents

Publication Publication Date Title
BR0115291A (pt) Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
ATE303369T1 (de) Glucocorticoid rezeptor modulatoren
BR0315317A (pt) 4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6
BRPI0409109A (pt) novos compostos
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0316950A (pt) Derivados de indazol como antagonistas de crf
DE60120077D1 (de) Modulatoren des Glucocorticoid-Rezeptors
BRPI9913542B8 (pt) derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
ATE301117T1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
BR0113585A (pt) Derivados quinazolina como antagonistas adrenérgicos alfa-1
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
ATE297929T1 (de) Azabicycloalkan-derivate zur verwendung als inhibitoren der serotonin-wiederaufnahme und als 5ht2a antagonisten
BR0316962A (pt) Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
BR0214695A (pt) Derivados de pirazol com anel fundido
BR0009561A (pt) 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase
BR0214674A (pt) Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico
PA8475401A1 (es) Compuestos de sulfonilbenceno como agentes antiinflamatorios/analgesicos
BR0207795A (pt) Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
BR0114424A (pt) Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 8A, 9AE 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.